Biohaven Pharmaceutical Holding Co Ltd
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase… Read more
Biohaven Pharmaceutical Holding Co Ltd (BHVN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -2.509x
Based on the latest financial reports, Biohaven Pharmaceutical Holding Co Ltd (BHVN) has a cash flow conversion efficiency ratio of -2.509x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-130.66 Million) by net assets ($52.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biohaven Pharmaceutical Holding Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Biohaven Pharmaceutical Holding Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biohaven Pharmaceutical Holding Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biohaven Pharmaceutical Holding Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Paladin Energy Ltd
OTCQX:PALAF
|
-0.003x |
|
Leroy Seafood Group ASA
LSE:0GM2
|
0.061x |
|
Birchcliff Energy Ltd.
PINK:BIREF
|
0.045x |
|
C3 Ai Inc
NYSE:AI
|
-0.062x |
|
Indian Energy Exchange Limited
NSE:IEX
|
-0.007x |
|
DBV Technologies
NASDAQ:DBVT
|
-0.614x |
|
Xior Student Housing NV
PINK:XIORF
|
0.014x |
|
Jamf Holding
NASDAQ:JAMF
|
0.083x |
Annual Cash Flow Conversion Efficiency for Biohaven Pharmaceutical Holding Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Biohaven Pharmaceutical Holding Co Ltd from 2017 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $52.07 Million | $-609.44 Million | -11.704x | -750.85% |
| 2024-12-31 | $423.44 Million | $-582.45 Million | -1.376x | -77.47% |
| 2023-12-31 | $427.98 Million | $-331.73 Million | -0.775x | -40.28% |
| 2022-12-31 | $538.77 Million | $-297.69 Million | -0.553x | +64.13% |
| 2021-12-31 | $94.69 Million | $-145.84 Million | -1.540x | -55.69% |
| 2020-12-31 | $76.78 Million | $-75.96 Million | -0.989x | -101.95% |
| 2019-12-31 | $-7.42 Million | $-377.33 Million | 50.826x | +3990.94% |
| 2018-12-31 | $150.92 Million | $-197.14 Million | -1.306x | -81.82% |
| 2017-12-31 | $131.97 Million | $-94.81 Million | -0.718x | -- |